How long you take Tagrisso depends on why you’re taking it. For early-stage lung cancer after surgery, the maximum is 3 years. For advanced or metastatic lung cancer, you take it indefinitely until it stops working or side effects become too severe. In clinical practice, patients with advanced disease stay on Tagrisso for a median of about 22 months before the cancer finds a way to grow again.
After Surgery: A 3-Year Cap
If you had surgery for early-stage non-small cell lung cancer with an EGFR mutation, Tagrisso is used as adjuvant therapy, meaning it’s given afterward to reduce the chance of the cancer coming back. The FDA-approved recommendation is to take 80 mg once daily for up to 3 years. You stop sooner if the cancer recurs or if you develop side effects serious enough to warrant discontinuation.
That 3-year limit comes from the ADAURA trial, which tested Tagrisso against a placebo in this exact setting. Once the 3 years are up, you stop the medication. There is no current recommendation to continue beyond that point for early-stage disease.
Advanced Cancer: No Fixed Endpoint
For metastatic or locally advanced lung cancer, the rules are different. There’s no preset time limit. You take Tagrisso for as long as it keeps the cancer in check and your body tolerates it. Some patients stay on it for years.
In real-world data, the median progression-free survival for patients starting Tagrisso as a first-line treatment is about 22 months. That means roughly half of patients are still benefiting from the drug past the 22-month mark, and roughly half see their cancer progress before that point. Individual experiences vary widely. Some people remain on Tagrisso for three, four, or even five years, while others may need to switch treatments sooner.
Results from the FLAURA2 trial showed that combining Tagrisso with chemotherapy extended median overall survival to 47.5 months compared to 37.6 months with Tagrisso alone. The 3-year survival rate was 63% with the combination versus 51% with Tagrisso by itself. This combination approach is now an option for some patients and can influence how long the treatment remains effective.
Why Tagrisso Eventually Stops Working
Tagrisso targets a specific mutation on cancer cells that drives their growth. Over time, cancer cells develop new genetic changes that allow them to bypass the drug’s effects. This acquired resistance is considered inevitable, though the timeline varies from person to person.
The resistance mechanisms fall into two broad categories. The first involves additional mutations on the same gene Tagrisso targets, most notably a mutation called C797S. The second category involves the cancer activating entirely different growth pathways, gene fusions, or even transforming into a different cell type altogether. Understanding which resistance mechanism develops helps oncologists decide what treatment to try next.
Side Effects That Can Shorten Treatment
Most people tolerate Tagrisso well enough to stay on it for the full intended duration, but certain serious side effects require stopping the drug permanently. These aren’t common, but they’re important to know about.
- Lung inflammation (interstitial lung disease): A potentially dangerous swelling in the lungs that causes shortness of breath and cough. This requires permanent discontinuation.
- Heart rhythm changes: Tagrisso can affect the heart’s electrical timing. If this leads to dangerous arrhythmias, the drug must be stopped.
- Heart muscle weakness: Symptomatic heart failure means Tagrisso needs to be permanently discontinued.
- Severe skin reactions: Rare but serious conditions involving widespread skin blistering or peeling require stopping treatment.
- Severe blood cell problems: A condition called aplastic anemia, where the bone marrow stops producing enough blood cells, requires permanent discontinuation if confirmed.
For other side effects rated as severe, the typical approach is to pause the medication and see if symptoms improve within three weeks. If they don’t resolve in that window, the drug is stopped for good.
What Monitoring Looks Like Long-Term
Staying on Tagrisso means regular check-ins to make sure the drug is still working and your body is handling it. You’ll have periodic blood draws to check your blood cell counts and electrolyte levels. If you have risk factors for heart problems, or if you’re on the combination regimen with chemotherapy, your doctor will monitor your heart function with imaging that measures how well your heart pumps.
Electrocardiograms (EKGs) are done periodically to watch for heart rhythm changes, especially if you have preexisting risk factors. Imaging scans, typically CT scans, are used to track the cancer itself, though the exact frequency varies based on your clinical situation and how long you’ve been stable on the medication. Early on, scans tend to be more frequent. If you’ve been stable for a long time, the intervals between scans may stretch out.
The daily routine itself is straightforward: one pill, once a day, with or without food. For many patients, the biggest adjustment isn’t the medication schedule but the ongoing monitoring and the uncertainty of not knowing exactly how long the drug will keep working.